Amlodipine / Valsartan Mylan

Riik: Euroopa Liit

keel: inglise

Allikas: EMA (European Medicines Agency)

Osta kohe

Infovoldik Infovoldik (PIL)
17-08-2023
Toote omadused Toote omadused (SPC)
17-08-2023
Avaliku hindamisaruande Avaliku hindamisaruande (PAR)
06-04-2016

Toimeaine:

Amlodipine besilate, valsartan

Saadav alates:

Mylan Pharmaceuticals Limited

ATC kood:

C09DB01

INN (Rahvusvaheline Nimetus):

amlodipine, valsartan

Terapeutiline rühm:

Agents acting on the renin-angiotensin system

Terapeutiline ala:

Hypertension

Näidustused:

Treatment of essential hypertension.Amlodipine/Valsartan Mylan is indicated in adults whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.

Toote kokkuvõte:

Revision: 11

Volitamisolek:

Authorised

Loa andmise kuupäev:

2016-03-22

Infovoldik

                                45
B. PACKAGE LEAFLET
46
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
AMLODIPINE/VALSARTAN MYLAN 5 MG/80 MG FILM-COATED TABLETS
AMLODIPINE/VALSARTAN MYLAN 5 MG/160 MG FILM-COATED TABLETS
AMLODIPINE/VALSARTAN MYLAN 10 MG/160 MG FILM-COATED TABLETS
amlodipine/valsartan
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Amlodipine/Valsartan Mylan is and what it is used for
2.
What you need to know before you take Amlodipine/Valsartan Mylan
3.
How to take Amlodipine/Valsartan Mylan
4.
Possible side effects
5.
How to store Amlodipine/Valsartan Mylan
6.
Contents of the pack and other information
1.
WHAT AMLODIPINE/VALSARTAN MYLAN IS AND WHAT IT IS USED FOR
Amlodipine/Valsartan Mylan tablets contain two active substances
called amlodipine and valsartan.
Both of these substances help to control high blood pressure.
−
Amlodipine belongs to a group of substances called “calcium channel
blockers”. Amlodipine
stops calcium from moving into the blood vessel wall which stops the
blood vessels from
tightening.
−
Valsartan belongs to a group of substances called “angiotensin-II
receptor antagonists”.
Angiotensin II is produced by the body and makes the blood vessels
tighten, thus increasing the
blood pressure. Valsartan works by blocking the effect of angiotensin
II.
This means that both of these substances help to stop the blood
vessels tightening. As a result, the
blood vessels relax and blood pressure is lowered.
Amlodipine/Valsartan Mylan is used to treat high blood pressure in
adults whose blood p
                                
                                Lugege kogu dokumenti
                                
                            

Toote omadused

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets
Amlodipine/Valsartan Mylan 5 mg/160 mg film-coated tablets
Amlodipine/Valsartan Mylan 10 mg/160 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets
Each film-coated tablet contains 5 mg of amlodipine (as amlodipine
besilate) and 80 mg of valsartan.
Amlodipine/Valsartan Mylan 5 mg/160 mg film-coated tablets
Each film-coated tablet contains 5 mg of amlodipine (as amlodipine
besilate) and 160 mg of valsartan.
Amlodipine/Valsartan Mylan 10 mg/160 mg film-coated tablets
Each film-coated tablet contains 10 mg of amlodipine (as amlodipine
besilate) and 160 mg of
valsartan.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet
Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets
Light yellow, round, approximately 9 mm diameter, biconvex film-coated
tablet debossed with “AV1”
on one side and “M” on the other side.
Amlodipine/Valsartan Mylan 5 mg/160 mg film-coated tablets
Yellow, oval, approximately 15.6 mm × 7.8 mm, biconvex film-coated
tablet debossed with “AV2” on
one side and “M” on the other side.
Amlodipine/Valsartan Mylan 10 mg/160 mg film-coated tablets
Light brown, oval, approximately 15.6 mm × 7.8 mm, biconvex
film-coated tablet debossed with
“AV3” on one side and “M” on the other side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of essential hypertension.
Amlodipine/Valsartan Mylan is indicated in adults whose blood pressure
is not adequately controlled
on amlodipine or valsartan monotherapy.
_ _
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
3
The recommended dose of Amlodipine/Valsartan Mylan is one tablet per
day.
_Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets _
Amlodipine/Valsartan Mylan 5 mg/80 mg may be administered in patients
whose blood pressure is not
adequately controlled with amlodipine 5 mg
                                
                                Lugege kogu dokumenti
                                
                            

Dokumendid teistes keeltes

Infovoldik Infovoldik bulgaaria 17-08-2023
Toote omadused Toote omadused bulgaaria 17-08-2023
Avaliku hindamisaruande Avaliku hindamisaruande bulgaaria 06-04-2016
Infovoldik Infovoldik hispaania 17-08-2023
Toote omadused Toote omadused hispaania 17-08-2023
Avaliku hindamisaruande Avaliku hindamisaruande hispaania 06-04-2016
Infovoldik Infovoldik tšehhi 17-08-2023
Toote omadused Toote omadused tšehhi 17-08-2023
Avaliku hindamisaruande Avaliku hindamisaruande tšehhi 06-04-2016
Infovoldik Infovoldik taani 17-08-2023
Toote omadused Toote omadused taani 17-08-2023
Avaliku hindamisaruande Avaliku hindamisaruande taani 06-04-2016
Infovoldik Infovoldik saksa 17-08-2023
Toote omadused Toote omadused saksa 17-08-2023
Avaliku hindamisaruande Avaliku hindamisaruande saksa 06-04-2016
Infovoldik Infovoldik eesti 17-08-2023
Toote omadused Toote omadused eesti 17-08-2023
Avaliku hindamisaruande Avaliku hindamisaruande eesti 06-04-2016
Infovoldik Infovoldik kreeka 17-08-2023
Toote omadused Toote omadused kreeka 17-08-2023
Avaliku hindamisaruande Avaliku hindamisaruande kreeka 06-04-2016
Infovoldik Infovoldik prantsuse 17-08-2023
Toote omadused Toote omadused prantsuse 17-08-2023
Avaliku hindamisaruande Avaliku hindamisaruande prantsuse 06-04-2016
Infovoldik Infovoldik itaalia 17-08-2023
Toote omadused Toote omadused itaalia 17-08-2023
Avaliku hindamisaruande Avaliku hindamisaruande itaalia 06-04-2016
Infovoldik Infovoldik läti 17-08-2023
Toote omadused Toote omadused läti 17-08-2023
Avaliku hindamisaruande Avaliku hindamisaruande läti 06-04-2016
Infovoldik Infovoldik leedu 17-08-2023
Toote omadused Toote omadused leedu 17-08-2023
Avaliku hindamisaruande Avaliku hindamisaruande leedu 06-04-2016
Infovoldik Infovoldik ungari 17-08-2023
Toote omadused Toote omadused ungari 17-08-2023
Avaliku hindamisaruande Avaliku hindamisaruande ungari 06-04-2016
Infovoldik Infovoldik malta 17-08-2023
Toote omadused Toote omadused malta 17-08-2023
Avaliku hindamisaruande Avaliku hindamisaruande malta 06-04-2016
Infovoldik Infovoldik hollandi 17-08-2023
Toote omadused Toote omadused hollandi 17-08-2023
Avaliku hindamisaruande Avaliku hindamisaruande hollandi 06-04-2016
Infovoldik Infovoldik poola 17-08-2023
Toote omadused Toote omadused poola 17-08-2023
Avaliku hindamisaruande Avaliku hindamisaruande poola 06-04-2016
Infovoldik Infovoldik portugali 17-08-2023
Toote omadused Toote omadused portugali 17-08-2023
Avaliku hindamisaruande Avaliku hindamisaruande portugali 06-04-2016
Infovoldik Infovoldik rumeenia 17-08-2023
Toote omadused Toote omadused rumeenia 17-08-2023
Avaliku hindamisaruande Avaliku hindamisaruande rumeenia 06-04-2016
Infovoldik Infovoldik slovaki 17-08-2023
Toote omadused Toote omadused slovaki 17-08-2023
Avaliku hindamisaruande Avaliku hindamisaruande slovaki 06-04-2016
Infovoldik Infovoldik sloveeni 17-08-2023
Toote omadused Toote omadused sloveeni 17-08-2023
Avaliku hindamisaruande Avaliku hindamisaruande sloveeni 06-04-2016
Infovoldik Infovoldik soome 17-08-2023
Toote omadused Toote omadused soome 17-08-2023
Avaliku hindamisaruande Avaliku hindamisaruande soome 06-04-2016
Infovoldik Infovoldik rootsi 17-08-2023
Toote omadused Toote omadused rootsi 17-08-2023
Avaliku hindamisaruande Avaliku hindamisaruande rootsi 06-04-2016
Infovoldik Infovoldik norra 17-08-2023
Toote omadused Toote omadused norra 17-08-2023
Infovoldik Infovoldik islandi 17-08-2023
Toote omadused Toote omadused islandi 17-08-2023
Infovoldik Infovoldik horvaadi 17-08-2023
Toote omadused Toote omadused horvaadi 17-08-2023
Avaliku hindamisaruande Avaliku hindamisaruande horvaadi 06-04-2016